Twenty-five years inside biotech deals —
now working for your next milestone.
Dr. Jahan Ali helps biotech founders move their companies forward, drawing on a career spent building biotech companies from the inside: negotiating partnerships, investing in early-stage ventures, and designing the programs that get founders to their next inflection point.
business plans
& foundation grants
collaboration deals
leadership
advisory

of Medicine
University
A rare, on-the-ground view of what early-stage companies actually need.
Dr. Jahan Ali works with biotech founders to move their companies forward — drawing on 25 years spent building biotech companies from the inside, negotiating partnerships, investing in early-stage ventures, and designing the programs that help founders reach their next milestone.
She has negotiated a wide range of agreements, including in- and out-licensing, research collaborations, manufacturing agreements, and stock purchase agreements — experience built across roles as Director of Business Development at the International AIDS Vaccine Initiative, a licensing professional at the Hospital for Special Surgery and Mount Sinai, and life science investment lead at the Partnership Fund, a private fund founded by Henry Kravis.
At the Bioventure eLab at Weill Cornell, she built an investor conference, mentorship program, and startup competitions for founders. At SymBiosis Capital, she secured a multi-million-dollar commitment from investors to grow the regional life science ecosystem.
In her consulting work, she helps companies secure non-dilutive funding — including SBIR/STTR, U.S. EDA, New York State, and foundation grants — and build the market research and business plans behind it.
Built across the deal table and the lab bench
Director of Business Development
International AIDS Vaccine Initiative (IAVI)Led partnership and licensing strategy across a global vaccine R&D portfolio.
Licensing Professional
Hospital for Special Surgery & Mount SinaiManaged in- and out-licensing of institutional technology and research agreements.
Life Science Investment Lead
The Partnership Fund (founded by Henry Kravis)Sourced and evaluated early-stage life science investments for a private fund.
Program Builder
Bioventure eLab, Weill CornellBuilt an investor conference, mentorship program, and startup competitions for founders.
Ecosystem Lead
SymBiosis CapitalSecured a multi-million-dollar commitment from investors to grow the regional life science ecosystem.
Current roles
GynStrong
NomoCan
VoiceLove
Digitalis Commons
Four places I plug in
Each is a clause in the same deal: getting your company to its next milestone without giving up more than it has to.
Non-dilutive funding
Strategy and hands-on support to secure grant funding without giving up equity.
- SBIR / STTR
- U.S. Economic Development Administration (EDA)
- New York State programs
- Foundation grants
Market research & business plans
The research and narrative that grant reviewers, partners, and investors need to say yes.
- Competitive & market landscape analysis
- Business plans built around your funding strategy
Partnership & licensing negotiation
Deal experience across the full range of agreements an early-stage biotech will face.
- In- and out-licensing
- Research collaboration agreements
- Manufacturing agreements
- Stock purchase agreements
Fractional executive leadership
Operating leadership for companies that need executive bandwidth without a full-time hire.
- Fractional CEO / COO engagements
- Board & advisory roles
Field notes
Notes from the deal table, written for founders who'd rather hear it straight.
What a term sheet actually tells you about a partner
The clauses founders skim past are usually the ones that matter most a year later.
The non-dilutive funding most founders never apply for
SBIR/STTR and state programs move slowly — which is exactly why you should start now.
Out-licensing without giving away your leverage
What twenty-five years of licensing deals taught me about walking away well.
Hiring a fractional executive before you think you need one
The companies that wait until they're stuck wait too long.
Conversations on the road to a deal
Short, candid conversations with founders, investors, and operators about what it actually takes to move a biotech company forward.
Negotiating your first licensing deal
What changes once a term sheet is on the table, and where first-time founders give away the most.
Grants over equity: building a non-dilutive runway
A practical walkthrough of how SBIR/STTR and state grant strategy actually fits into a fundraising plan.
What a fractional exec sees in the first 90 days
The patterns that show up across every early-stage company, and the ones that are unique to yours.
Let's talk about your next milestone.
Whether it's a grant strategy, a partnership in motion, or fractional leadership — happy to start with a short call.
- GynStrongFractional CEO
- NomoCanFractional COO
- VoiceLoveBoard Advisor
- Digitalis CommonsExecutive in Residence